Naval and Veterans Hospital

Athens, Greece

Naval and Veterans Hospital

Athens, Greece

Time filter

Source Type

Mourtzikou A.,National and Kapodistrian University of Athens | Stamouli M.,Naval and Veterans Hospital | Kroupis C.,National and Kapodistrian University of Athens | Christodoulou S.,National and Kapodistrian University of Athens | And 5 more authors.
Clinical Laboratory | Year: 2012

Background: Colorectal cancer (CRC) is a major public health problem and one of the leading causes of death worldwide. The aim of our study was: a) to determine the CEA, CA 19-9, EGFR, and EpCAM (GA733-2) levels both in healthy volunteers and in colorectal cancer patients, b) to evaluate the ELISA method for EGFR and EpCAM (GA733-2) measurement, and c) to correlate the tumor marker levels with clinicopathological findings in the CRC patients group. Methods: Our study was conducted on 50 blood samples obtained from CRC patients and 40 blood samples from healthy individuals. CEA and CA 19-9 measurements were performed using electrochemiluminescence immuneassay technology, while EGFR and EpCAM (GA733-2) measurements were performed by an in-house enzyme immunoassay. Results: CEA, CA 19-9, and EpCAM (GA733-2) levels were higher in the CRC patients group than in the control group. EGFR levels were lower in the patients group than in the control group. The mean levels of CA 19-9 and EpCAM (GA733-2) vary at different colon cancer stages. CEA, CA19-9, and EpCAM (GA733-2) vary according to performance status. Conclusions: CEA, CA 19-9, and EpCAM (GA733-2) showed similar specificity (80%, 80% and 84%, respectively). EGFR showed the lowest sensitivity and specificity. CA 19-9 was the marker with the highest sensitivity. The need for convenient tumour marker tests with high sensitivity is of great importance for early diagnosis and monitoring of CRC.


Mourtzikou A.,National and Kapodistrian University of Athens | Kosmas K.,Anti Cancer Oncological Hospital St Savvas | Marouga A.,National and Kapodistrian University of Athens | Stamouli M.,Naval and Veterans Hospital | And 2 more authors.
Clinical Laboratory | Year: 2012

Backgound: Endometrial adenocarcinoma is the most common gynecologic malignancy and is the fifth most frequently diagnosed cancer in women. The objective of the present study was to determine the expression of a proliferation marker, Ki-67 and an apoptosis inhibitor, Bcl-2, by double-label staining in endometrial adenocarcinomas and in normal endometrium samples, to evaluate the differences in the immunocytochemical expression of Ki-67 and Bcl-2, and finally to correlate the results with tumor grade and stage. Methods: This study was carried on 270 endometrial samples, collected during a 27 month period, freshly resected from women who underwent total abdominal hysterectomy. Results: Ki-67 and Bcl-2 expressions were studied by immunocytochemistry. Bcl-2 expression was strong and homogeneous in normal (proliferative, secretory and atrophic) endometrium and more frequent in low-grade endometrioid carcinomas. Completely negative staining of Bcl-2 was found to be strictly related to high-grade endometrioid carcinomas. Ki-67 expression was higher in patients with high-grade endometrioid carcinomas. Proliferative endometrium showed inconclusive Ki-67 expression levels and in the secretory endometrium Ki-67 positive cells were remarkably diminished and even disappeared. Completely negative staining of Ki-67 was found to be strictly related to atrophic endometrium. Conclusions: Immunocytochemical double-label staining can be used to display the distribution of Bcl-2 and Ki-67 cells in endometrioid carcinomas as well as normal endometrium, and, in addition to cytomorphologic features, contributes to its accurate diagnosis.


Stamouli M.,Naval and Veterans Hospital | Pouliakis A.,National and Kapodistrian University of Athens | Mourtzikou A.,National and Kapodistrian University of Athens | Skliris A.,Naval and Veterans Hospital | And 3 more authors.
Clinical Laboratory | Year: 2014

Background: Diabetes mellitus (DM) is one of the most serious global health problems. In Greece, DM constitutes a public health problem and is highly associated with decreasing levels of physical activity, increasing obesity rates, population ageing, and unhealthy lifestyle and dietary behaviors.Materials: In this study we evaluated the sera from 800 type 2 diabetic patients recruited during a three year period of time and 200 age matched controls without any clinical history of diabetes. For each subject we measured levels of fasting glucose (GLU), total cholesterol (TCHOL), triglycerides (TRG), high density lipoproteins (HDL-C), and glycosylated hemoglobin (GHbAlc) and calculated levels of low density lipoproteins (LDL-C). The aims of our study were to find characteristics of lipid parameters in the population under study, to find gender differences in the parameters, to evaluate correlations between pairs of lipid parameters, and to compare the lipid parameters between patients and healthy controls focusing on patient gender. For this purpose we analyzed the data using descriptive statistics, x-square test, logistic regression and ROC curve analysis.Results: According to our results, 70.0% of diabetic patients presented at least one lipid abnormality. Elevated LDL-C, elevated TCHOL, elevated TRG, and reduced HDL-C levels were noted in 28.37%, 36.37%, 39.01%, and 30.12% of the patients, respectively. The combination of elevated TRG and reduced HDL-C was the most prevalent of the combined lipid abnormalities. Moreover, there are statistically significant differences in the levels of HDL-C, TCHOL, TRG, and GLU between men and women. In contrast, no differences were observed in levels of GHbAlc.Conclusions: We identified an important linear relationship between LDL-C and TCHOL (LDL-C = -28.69 + TCHOL ∗ 0.75, adjusted R2 = 76.96%. Finally, we calculated optimal thresholds for GLU and GHblAc levels using two methodologies: overall accuracy maximization or sensitivity-specificity minimization for the identification of patient from healthy controls. Differences in the optimal thresholds between men and women were not observed.


Damaskos C.,National and Kapodistrian University of Athens | Karatzas T.,National and Kapodistrian University of Athens | Nikolidakis L.,Ygeias Melathron Hospital | Kostakis I.D.,National and Kapodistrian University of Athens | And 5 more authors.
Anticancer Research | Year: 2015

Pancreatic carcinoma is one of the leading causes of cancer death. Current standard treatments include surgical resection, chemotherapy and radiotherapy but patient's prognosis remains poor and present severe side-effects. Contemporary oncology found a wide variety of novel anticancer drugs that regulate the epigenetic mechanisms of tumor genesis. Histone deacetylases (HDACs) are enzymes with pleiotropic activities that control critical functions of the cell through regulation of the acetylation states of histone proteins and other non-histone protein targets. They are divided into four groups, each with different localization in the cell, role and structure. Histone deacetylase inhibitors (HDACIs) are substances, which inhibit the function of HDACs. We recognize four leading groups (hydroxamic acid, cyclic tetrapeptide, benzamide, aliphatic acid). There are many HDACIs currently in pre-clinical and two (vorinostat, romidepsin) in clinical stages of investigation for pancreatic cancer. Numerous studies argue for the use HDACIs as monotherapy, others suggest that combination of HDACIs with other antitumor drugs has better therapeutic results. This review focuses on the use of HDACIs as novel anticancer drugs and will explain the mechanisms of therapeutic effect on pancreatic cancer. © 2015, International Institute of Anticancer Research. All rights reserved.


Dellis A.,National and Kapodistrian University of Athens | Deliveliotis C.,Urologic | Kalentzos V.,Naval and Veterans Hospital | Vavasis P.,Naval and Veterans Hospital | Skolarikos A.,Urologic
International Braz J Urol | Year: 2014

Purpose: To examine the safety and efficacy of hyperbaric oxygen as the primary treatment for Grade IV radiation-induced haemorrhagic cystitis. Materials and Methods: Hyperbaric oxygen was prospectively applied as a primary treatment option in 11 patients with Grade IV radiation cystitis. Primary endpoint was the incidence of complete and partial response to treatment. Secondary endpoints included the duration of response, the correlation of treatment success-rate to the interval between the onset of haematuria and initiation of therapy, blood transfusion need and total radiation dose, the number of sessions to success, the avoidance of surgery and the overall survival. Results: All patients completed therapy without complications for a mean follow-up of 17.82 months (range 3 to 34). Mean number of sessions needed was 32.8 (range 27 to 44). Complete and partial response rate was 81.8% and 18.2%, respectively. However, in three patients the first treatment session was not either sufficient or durable giving a 72.7% rate of durable effect. Interestingly, all 9 patients with complete response received therapy within 6 months of the haematuria onset compared to the two patients with partial response who received therapy at 8 and 10 months from the haematuria onset, respectively (p = 0.018). The need for blood transfusion (p = 0.491) and the total radiation dose (p = 0.259) were not correlated to success-rate. One patient needed cystectomy, while all patients were alive at the end of follow-up. Conclusions: Early primary use of hyperbaric oxygen to treat radiation-induced grade IV cystitis is an effective and safe treatment option.


PubMed | Urologic, Naval and Veterans Hospital and National and Kapodistrian University of Athens
Type: Journal Article | Journal: International braz j urol : official journal of the Brazilian Society of Urology | Year: 2014

To examine the safety and efficacy of hyperbaric oxygen as the primary treatment for Grade IV radiation-induced haemorrhagic cystitis.Hyperbaric oxygen was prospectively applied as a primary treatment option in 11 patients with Grade IV radiation cystitis. Primary endpoint was the incidence of complete and partial response to treatment. Secondary endpoints included the duration of response, the correlation of treatment success-rate to the interval between the onset of haematuria and initiation of therapy, blood transfusion need and total radiation dose, the number of sessions to success, the avoidance of surgery and the overall survival.All patients completed therapy without complications for a mean follow-up of 17.82 months (range 3 to 34). Mean number of sessions needed was 32.8 (range 27 to 44). Complete and partial response rate was 81.8% and 18.2%, respectively. However, in three patients the first treatment session was not either sufficient or durable giving a 72.7% rate of durable effect. Interestingly, all 9 patients with complete response received therapy within 6 months of the haematuria onset compared to the two patients with partial response who received therapy at 8 and 10 months from the haematuria onset, respectively (p = 0.018). The need for blood transfusion (p = 0.491) and the total radiation dose (p = 0.259) were not correlated to success-rate. One patient needed cystectomy, while all patients were alive at the end of follow-up.Early primary use of hyperbaric oxygen to treat radiation-induced grade IV cystitis is an effective and safe treatment option.


PubMed | Academy of Athens, Ygeias Melathron Hospital, National and Kapodistrian University of Athens and Naval and Veterans Hospital
Type: Journal Article | Journal: Anticancer research | Year: 2015

Pancreatic carcinoma is one of the leading causes of cancer death. Current standard treatments include surgical resection, chemotherapy and radiotherapy but patients prognosis remains poor and present severe side-effects. Contemporary oncology found a wide variety of novel anticancer drugs that regulate the epigenetic mechanisms of tumor genesis. Histone deacetylases (HDACs) are enzymes with pleiotropic activities that control critical functions of the cell through regulation of the acetylation states of histone proteins and other non-histone protein targets. They are divided into four groups, each with different localization in the cell, role and structure. Histone deacetylase inhibitors (HDACIs) are substances, which inhibit the function of HDACs. We recognize four leading groups (hydroxamic acid, cyclic tetrapeptide, benzamide, aliphatic acid). There are many HDACIs currently in pre-clinical and two (vorinostat, romidepsin) in clinical stages of investigation for pancreatic cancer. Numerous studies argue for the use HDACIs as monotherapy, others suggest that combination of HDACIs with other antitumor drugs has better therapeutic results. This review focuses on the use of HDACIs as novel anticancer drugs and will explain the mechanisms of therapeutic effect on pancreatic cancer.


Stamouli M.,Naval and Veterans Hospital | Panagiotou I.,Naval and Veterans Hospital | Kairis D.,Naval and Veterans Hospital | Michopoulou A.,Naval and Veterans Hospital | And 2 more authors.
Clinical Laboratory | Year: 2012

Background: Hepatitis C is a major public health problem. HCV infection contributes to progressive liver disease, cirrhosis, and hepatocellular carcinoma. HCV has high genetic heterogeneity and is classified into various genotypes and subtypes. Regional differences exist in their distribution. The aim of this study was to investigate the relative frequency of HCV genotypes in Greek patients with chronic infection. Methods: We evaluated 82 patients with chronic HCV infection, both males and females, belonging to different risk groups. We performed viral load measurement and HCV genotyping in all specimens. Results: HCV genotype 3 was the most prevalent (41.5%) followed by genotype 1 (34.1%), 2 (12.2%), 4 (10.9%), and 5 (1.2%). Genotype 6 was not detected in any patient. Most prevalent subtypes were 3a (32.9%), lb (26.8%), and 2a (6.1%). Fourteen subjects revealed mixed infections within types. There were no cases with mixed infections across types. Conclusions: Our data indicate that genotypes 3a and lb are the most prevalent in Greek patients. Genotype 3a is predominant in younger patients and also in male patients. Moreover, HCV genotype distribution is in continuous temporal change in Greece.


PubMed | Naval and Veterans Hospital
Type: Journal Article | Journal: Clinical laboratory | Year: 2012

Hepatitis C is a major public health problem. HCV infection contributes to progressive liver disease, cirrhosis, and hepatocellular carcinoma. HCV has high genetic heterogeneity and is classified into various genotypes and subtypes. Regional differences exist in their distribution. The aim of this study was to investigate the relative frequency of HCV genotypes in Greek patients with chronic infection.We evaluated 82 patients with chronic HCV infection, both males and females, belonging to different risk groups. We performed viral load measurement and HCV genotyping in all specimens.HCV genotype 3 was the most prevalent (41.5%) followed by genotype 1 (34.1%), 2 (12.2%), 4 (10.9%), and 5 (1.2%). Genotype 6 was not detected in any patient. Most prevalent subtypes were 3a (32.9%), 1b (26.8%), and 2a (6.1%). Fourteen subjects revealed mixed infections within types. There were no cases with mixed infections across types.Our data indicate that genotypes 3a and 1b are the most prevalent in Greek patients. Genotype 3a is predominant in younger patients and also in male patients. Moreover, HCV genotype distribution is in continuous temporal change in Greece.


The diagnosis of autoimmune diseases depends on clinical history, physical examination, and laboratory detection of specific autoantibodies directed against nuclear or cytoplasmic antigens. The aim of this study was to investigate the types and prevalence of serum ANA, anti-dsDNA, and anti-ENA antibodies in a population examined at the Immunology Laboratory of the Naval Hospital of Athens and their correlation with patient age and gender.We evaluated the sera of 3000 patients, both male and female, aged between 18 and 75 years old, born in different parts of Greece. All requests for ANA detection were performed by enzyme linked immunoassay (ELI SA). All ELISA borderline, weak positive and pbsitive results were run on the indirect immunofluorescence assay (IFA) on Hep-2 cells. Anti-dsDNA antibodies were detected by IFA on Crithidia luciliae substrate slides. Antibodies to Sm, RNP, SS-A(Ro), SS-B(La), Jo-1, and Scl-70 were determined by an immunodot qualitative test.206 patients were positive for ANA, representing a prevalence of 6.87%. The positive samples demonstrated the expected variety of titers and reactivity patterns. 9 samples (4.37%) presented anti-dsDNA positive result and 44 (21.36%) presented reactivity to various ENA autoantibodies. All the examined autoantibodies presented a higher prevalence among women.In this study we estimated the prevalence of ANA, anti-dsDNA, and anti-ENA antibodies in samples of 3000 sera. We followed the strategy of performing immunofluorescence testing in order to confirm positive ELISA results, proposed by many scientists. We also evaluated autoantibody titers and fluorescence patterns, and we examined the correlation of autoantibody presence with patient age and gender.

Loading Naval and Veterans Hospital collaborators
Loading Naval and Veterans Hospital collaborators